Cargando…
Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
Current vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196663/ https://www.ncbi.nlm.nih.gov/pubmed/35240929 http://dx.doi.org/10.1080/21645515.2022.2043105 |
_version_ | 1784727244509282304 |
---|---|
author | Maguire, Greg |
author_facet | Maguire, Greg |
author_sort | Maguire, Greg |
collection | PubMed |
description | Current vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and dosing strategy to induce “physiological renormalization” to induce mimicry in the innate and adaptive immune systems in the respiratory tracts and sera, similar to that when the body encounters the natural infectious agent. |
format | Online Article Text |
id | pubmed-9196663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-91966632022-06-15 Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example Maguire, Greg Hum Vaccin Immunother Coronavirus – Commentary Current vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and dosing strategy to induce “physiological renormalization” to induce mimicry in the innate and adaptive immune systems in the respiratory tracts and sera, similar to that when the body encounters the natural infectious agent. Taylor & Francis 2022-03-03 /pmc/articles/PMC9196663/ /pubmed/35240929 http://dx.doi.org/10.1080/21645515.2022.2043105 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Coronavirus – Commentary Maguire, Greg Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
title | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
title_full | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
title_fullStr | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
title_full_unstemmed | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
title_short | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
title_sort | using a “systems therapeutic for physiological renormalization” approach to vaccine development. covid-19 as an example |
topic | Coronavirus – Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196663/ https://www.ncbi.nlm.nih.gov/pubmed/35240929 http://dx.doi.org/10.1080/21645515.2022.2043105 |
work_keys_str_mv | AT maguiregreg usingasystemstherapeuticforphysiologicalrenormalizationapproachtovaccinedevelopmentcovid19asanexample |